Physician profile
Jayshri Gamoth
NPI 1851340467
$3,844.85
in general payments reported to CMS, 2019-2025
28 companies · $452 in 2025
The $452 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $990 · 2020: $526 · 2021: $596 · 2022: $765 · 2023: $154 · 2024: $361 · 2025: $452.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $967.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $967.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $754.43 | 2019-2025 | |
| Amgen INC. | $348.98 | 2019-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $315.52 | 2019-2022 | |
| Genentech USA, INC. | $279.22 | 2019-2022 | |
| Ucb, INC. | $253.67 | 2019-2024 | Bimzelx |
| Janssen Biotech, INC. | $187.20 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $177.06 | 2022-2025 | Sotyktu |
| Regeneron Healthcare Solutions, INC. | $175.05 | 2019-2024 | Libtayo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $174.61 | 2022-2023 | Xifaxan |
| Pfizer INC. | $170.08 | 2019-2022 | |
| Genzyme Corporation | $139.21 | 2021-2022 | |
| Arcutis Biotherapeutics, INC. | $131.79 | 2025 | Zoryve |
| Galderma Laboratories, L.P. | $96.40 | 2019-2024 | |
| Celgene Corporation | $86.41 | 2019 | |
| Incyte Corporation | $84.74 | 2024-2025 | Opzelura, Opzelura |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $66.54 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $62.78 | 2019-2022 | |
| Strata Skin Sciences, INC. | $56.52 | 2025 | Xtrac |
| Leo Pharma INC. | $48.22 | 2019-2021 | |
| Lilly USA, LLC | $44.51 | 2022 | |
| Dusa Pharmaceuticals, INC. | $37.74 | 2019 | |
| Organogenesis INC. | $36.39 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.22 | 2022 | |
| Biowound Solutions, INC. | $20.52 | 2025 | Bio-Connekt |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $17.76 | 2022 | |
| Hill Dermaceuticals, INC. | $16.52 | 2025 | Tolak |
| Dermira, INC. | $16.18 | 2019 | |
| Mayne Pharma Commercial LLC | $14.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jayshri Gamoth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.